Compare PAGS & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAGS | TARS |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2017 | 2020 |
| Metric | PAGS | TARS |
|---|---|---|
| Price | $8.76 | $62.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $12.00 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 2.9M | 435.0K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.42% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $11.07 | $56.43 |
| Revenue Next Year | $7.26 | $30.19 |
| P/E Ratio | $7.74 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $7.74 | $38.51 |
| 52 Week High | $12.32 | $85.25 |
| Indicator | PAGS | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 54.83 |
| Support Level | $8.54 | $61.24 |
| Resistance Level | $10.32 | $66.36 |
| Average True Range (ATR) | 0.28 | 2.68 |
| MACD | 0.05 | 0.49 |
| Stochastic Oscillator | 32.04 | 83.35 |
PagSeguro Digital Ltd is a Brazilian-based company that acts as a provider of financial technology solutions focused on Micro-Merchants, Small Companies and Medium-Sized Companies (SMEs), in Brazil. The company provides a range of solutions and tools such as cash-in and cash-out options and provides access to working capital to help to manage its cash flow. It delivers an end-to-end digital ecosystem to address day-to-day financial needs, including receiving and spending funds and managing and growing businesses for clients. The company also offers the Free PagSeguro Digital Account delivering Cash-In Solutions, Online and In-Person Payment Tools, Online Payment Tools; and Web Check Outs offer tokenization, handling of shipping information, and others.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.